<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>KFF Health News</provider_name><provider_url>https://kffhealthnews.org</provider_url><author_name>khnshefalil</author_name><author_url>https://kffhealthnews.org/news/author/khnshefalil/</author_url><title>&#x2018;Pharma Bro&#x2019; Shkreli Is In Prison, But Daraprim&#x2019;s Price Is Still High - KFF Health News</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="bqqauvjL1U"&gt;&lt;a href="https://kffhealthnews.org/news/for-shame-pharma-bro-shkreli-is-in-prison-but-daraprims-price-is-still-high/"&gt;&#x2018;Pharma Bro&#x2019; Shkreli Is In Prison, But Daraprim&#x2019;s Price Is Still High&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://kffhealthnews.org/news/for-shame-pharma-bro-shkreli-is-in-prison-but-daraprims-price-is-still-high/embed/#?secret=bqqauvjL1U" width="600" height="338" title="&#x201C;&#x2018;Pharma Bro&#x2019; Shkreli Is In Prison, But Daraprim&#x2019;s Price Is Still High&#x201D; &#x2014; KFF Health News" data-secret="bqqauvjL1U" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://kffhealthnews.org/wp-content/uploads/sites/2/2018/05/shkreli-1350.jpg</thumbnail_url><thumbnail_width>1350</thumbnail_width><thumbnail_height>900</thumbnail_height><description>The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.</description></oembed>
